Hosted on MSN1mon
GKOS Stock Gains Following Positive Study Data on iDose PlatformImage Source: Zacks Investment Research iDose TR’s Clinical Success: The 36-Month Follow-Up Data Recent findings from a 36-month follow-up analysis of two Phase 3 pivotal trials underscore iDose ...
The firm says its “bullish” key opinion leader checks indicated the “disruptive potential” of iDose across the U.S. glaucoma treatment landscape over the next several years. The checks ...
Zacks Investment Research on MSN12d
GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?Glaukos Corporation GKOS reported record fourth-quarter 2024 revenues of $105.5 million, reflecting a 28% year-over-year ...
Strong growth in the US glaucoma franchise with record fourth-quarter net sales of $56.3 million, driven by the success of iDose TR. The company faces potential headwinds from foreign currency ...
The firm notes Glaukos reported Q4 sales above consensus, driven by iDose and OUS MIGS, offsetting weaker core U.S. MIGS due to LCD headwinds. 2025 sales guidance brackets the Street, with iDose ...
Local medical device companies last month posted fourth quarter results that exceeded analysts’ expectations.Irvine’s Masimo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback